Business
Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203
MOUNTAIN VIEW, Calif., June 26, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, hist
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/5316f109f0c3444fc6fe6c27b990049d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAODkH7RoRLEVparwP1NJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5316f109f0c3444fc6fe6c27b990049d","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ZeR.rmtPB0Ja5YOm0ZGMcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5316f109f0c3444fc6fe6c27b990049d","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control –","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"– ALTO-203, a non-stimulant compound which demonstrated pro-cognitive and wake-promoting effects, has the potential to address sustained attention abnormalities in EEG biomarker characterized patients –","length":202,"tagName":"p","attribs":{}},{"type":"text","content":"– Pharmacodynamic activity is aligned with the proposed mechanism of ALTO-203; improvements in attention and corresponding reductions in EEG theta/beta ratio, as well as response prediction biomarker replicate Phase 1 study findings –","length":234,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., June 26, 2025--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, histamine H3 inverse agonist, designed to modulate circuits underlying cognition, wakefulness, and alertness.","length":632,"tagName":"p"},{"type":"text","content":"The profile exhibited by ALTO-203 in the exploratory POC trial demonstrated clear effects on objective measures of attention and wake...